18+ • For Research & Educational Purposes Only • Not Medical Advice  Disclaimer
Peptide Wiki
Sexual HealthFDA Approved

PT-141 (Bremelanotide)

Melanocortin receptor agonist that acts centrally on the brain rather than the vascular system to enhance sexual function

Research Reality Check

Strong SupportGood evidence backs this claim.
ClaimSome people claim PT-141 (Bremelanotide) has clear value for sexual health research.
RealityThere is meaningful human evidence, but this page is still not personal medical advice.
Bottom LineUse the evidence score, sources, and safety notes before taking any claim seriously.
Why People Believe ThisSimple explanations and user stories can sound more certain than the research is.
Watch Out For
Guaranteed resultsExact protocols presented as provenAnecdotes used as proof
478Discussions
2Citations

Evidence Dossier

90Evidence

FDA Approved

Evidence score reflects source depth, citations, and research maturity. It is not a medical recommendation.

2Citations
478Discussions
Start Here

PT-141 (Bremelanotide) at a glance

A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.

Evidence score90FDA approved
Primary routeSubcutaneous InjectionRoute availability varies by context
Safety depthWell studiedReview safety notes before making assumptions
Community questions478Related discussions and experiences

PT-141 (bremelanotide) is a synthetic analog of alpha-melanocyte stimulating hormone (α-MSH) that acts on melanocortin receptors in the central nervous system. Unlike PDE5 inhibitors such as sildenafil, which work peripherally by relaxing blood vessels, PT-141 works centrally in the brain to activate sexual desire and arousal pathways.

How It Works

FDA-approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, PT-141 has since been used off-label by both men and women for libido enhancement and sexual dysfunction. Its central mechanism of action makes it effective even in cases where vascular interventions have failed.

The peptide typically requires subcutaneous injection 45 minutes to several hours before sexual activity. Because it acts on central pathways rather than vascular ones, PT-141 produces genuine desire and arousal rather than simply facilitating mechanical function.

Key Benefits

✓
Enhanced libido and sexual desire
✓
Improved arousal in both sexes
✓
Effective for sexual dysfunction unresponsive to PDE5 inhibitors
✓
Central mechanism - no cardiovascular dependence

Saves this peptide to your Watchlist and helps you find new research, news, and questions later.

Quick Dosing Reference
Dose Range0.5-2mg
FrequencyAs needed, 4-6 hours before activity
RouteSubQ injection
Experience LevelBeginner